8-Bromo-cAMP, sodium salt (Synonyms: 8-Br-cAMP, 8-Bromoadenosine 3',5'-cyclic monophosphate, 8-bromo-cAMP) |
| Catalog No.GC16929 |
8-Bromo-cAMP (8-Bromo-cAMP, sodium salt) es un análogo del AMPc permeable a las células que actúa como activador de la protenía quinasa de pendiente de CAMP(PKA activator).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 76939-46-3
Sample solution is provided at 25 µL, 10mM.
8-Bromo-cAMP (8-Bromo-cAMP, sodium salt) es un análogo del AMPc permeable a las células que actúa como activador de la protenía quinasa de pendiente de CAMP(PKA activator).Tiene la capacidad de inhibir el crecimiento de las células tumorales y facilitar la diferenciación tumoral[1-2].
8-Bromo-cAMP (20μM;24 h/48h)indujeron la diferenciación y apoptosis de las células de carcinoma de esófago humano Eca-109 [3]. 8-Bromo-cAMP (0.1/0.5 mM;10días)mejora la eficiencia de la inducción de la pluripotencia en las células de fibroblastos humanos[4]. 8-Bromo-cAMP (250 μM) inhibe la actividad de transporte de glucosa en las células placentarias de ratón en cultura[5]. 8-Bromo-cAMP(0-1mM) induce una respuesta prokiferativa en una línea celular leucémica dependiente de IL-3[6].
8-Bromo-cAMP (60 mg/kg/ día; 7 días; i.p)claramente el crecimiento del tumor CT26 en los ratones[7]. 8-Bromo-cAMP mejora las respuestas inmunitarias humorales y mediadas por las células inducidas por una vacuna de ADN contra el VIH-1 en los ratones[8].
References:
[1]. Chen TC, Hinton DR, et,al. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest. 1998 Feb;78(2):165-74. PMID: 9484714.
[2]. Li H, Chen HC, et,al.Identification of a rapidly dephosphorylating 95-kDa protein as elongation factor 2 during 8-Br-cAMP treatment of N1E115 neuroblastoma cells. Biochem Biophys Res Commun. 1995 Dec 5;217(1):131-7. doi: 10.1006/bbrc.1995.2754. PMID: 8526900.
[3]. Wang HM, Zheng NG, et,al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42. doi: 10.3748/wjg.v11.i41.6538. PMID: 16425431; PMCID: PMC4355801.
[4]. Wang Y, Adjaye J. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev Rep. 2011 Jun;7(2):331-41. doi: 10.1007/s12015-010-9209-3. PMID: 21120637.
[5]. Sakata M, Yamaguchi M, et,al. 8-Bromo-cAMP inhibits glucose transport activity in mouse placental cells in culture. J Endocrinol. 1996 Aug;150(2):319-27. doi: 10.1677/joe.0.1500319. PMID: 8869598.
[6]. Barge RM, Falkenburg JH, et,al. 8-Bromo-cAMP induces a proliferative response in an IL-3 dependent leukemic cell line and activates Erk 1,2 via a Shc-independent pathway. Biochim Biophys Acta. 1997 Feb 4;1355(2):141-6. doi: 10.1016/s0167-4889(96)00130-9. PMID: 9042334.
[7]. Wang S, Zhang Z, et,al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774. doi: 10.2147/OTT.S164982. PMID: 29997437; PMCID: PMC6033084.
[8]. Arai H, Xin KQ, et,al. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine. Gene Ther. 2000 Apr;7(8):694-702. doi: 10.1038/sj.gt.3301145. PMID: 10800093.
| Experimentos celulares [1]: | |
Líneas celulares | Las células Eca-109 (las células de carcinoma de esófago humano) |
Método de preparación | Las células se cultivaron con 8-Bromo-cAMP durante 24 h y 48h. |
Condiciones de reacción | 20μmol/L;24 h/48h |
Áreas de aplicación | El tratamiento con 8-Bromo-cAMP indujo diferenciación y apoptosis en las células Eca-109. |
| Experimentos con animales [2]: | |
Modelos animales | Los ratones BALB/c |
Método de preparación | Los ratones se sometieron a la implantación de tejido de carcinoma CT26 en el ciego.El grupo experimental recibió inyecciones intraperitoneales de 8-Bromo-cAMP,mientras que el grupo control recibió inyección de la solución salina normal. |
Forma de dosificación | 60 mg/kg/ día; 7 días; i.p |
Áreas de aplicación | 8-Bromo-cAMP (60 mg/kg/ día; 7 días; i.p)claramente el crecimiento del tumor CT26 en los ratones. |
References: [1]. Wang HM, Zheng NG, et,al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42. doi: 10.3748/wjg.v11.i41.6538. PMID: 16425431; PMCID: PMC4355801. [2]. Wang S, Zhang Z, et,al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774. doi: 10.2147/OTT.S164982. PMID: 29997437; PMCID: PMC6033084. | |
| Cas No. | 76939-46-3 | SDF | |
| Sinónimos | 8-Br-cAMP, 8-Bromoadenosine 3',5'-cyclic monophosphate, 8-bromo-cAMP | ||
| Chemical Name | sodium (4aR,6R,7R,7aS)-6-(6-amino-8-bromo-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide | ||
| Canonical SMILES | NC1=C(N=C(Br)N2[C@@H]3O[C@H](COP(O4)([O-])=O)[C@@H]4[C@H]3O)C2=NC=N1.[Na+] | ||
| Formula | C10H10BrN5NaO6P | M.Wt | 430.09 |
| Solubility | ≥ 43mg/mL in Water;DMSO : 250 mg/mL (581.29 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3251 mL | 11.6255 mL | 23.2509 mL |
| 5 mM | 465 μL | 2.3251 mL | 4.6502 mL |
| 10 mM | 232.5 μL | 1.1625 mL | 2.3251 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *